Have you seen our new ‘How I treat…’ features? Become a member (it’s free!) and discover the latest advice from fellow clinicians here >>>

Prior treatment with PD-1 improves safety of stem cell transplants in Hodgkin lymphoma

Written by Louis Gautier, Future Science Group

A recent study has demonstrated that treatment with PD-1 inhibitor immunotherapy prior to donor stem cell transplant in Hodgkin lymphoma is a safe and effective option. This contradicts previous studies that have suggested a likelihood of immune-related problems when the two therapies are used together. Presented by researchers from the Dana-Farber Cancer Institute (MA, USA) at the ASH 2019 Annual Meeting (7–10 December, FL, USA), this large retrospective cohort study has abated fears relating to the safety of PD-1 inhibitor immunotherapy by demonstrating it to be a safe and feasible strategy for treating patients with classical Hodgkin lymphoma (cHL) before...

To view this content, please register now for access

It's completely free